425: Enzon Stockholders Approve Reverse Split, Viskase Merger

Enzon Pharmaceuticals, Inc. announced that stockholders approved a 1-for-100 reverse stock split and the merger agreement with Viskase Companies, Inc.

Summary

• Stockholders of Enzon Pharmaceuticals, Inc. have approved a 1-for-100 reverse stock split.
• Stockholders also approved the Agreement and Plan of Merger with Viskase Companies, Inc.
• The Reverse Stock Split Proposal was approved by 40,993,338 shares, representing 55.2% of outstanding common stock.
• The Merger Proposal was approved by 42,350,448 shares, representing 57.1% of outstanding common stock.
• The requisite majority of outstanding shares as of the January 29, 2026 Record Date (74,214,603 shares) consented to both proposals.
• The consent solicitation concluded on February 11, 2026, at 8:00 a.m. Eastern Time.
• The closing of the merger is contingent upon the satisfaction or waiver of remaining conditions outlined in the Merger Agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive step towards the completion of a significant strategic transaction. Stockholder approval for both the reverse split and the merger indicates progress, though the merger's closing remains subject to further conditions and associated risks.

Positives

• Stockholder approval for both the reverse stock split and the merger with Viskase Companies, Inc. has been secured, moving the transaction forward.
• The successful consent solicitation indicates strong stockholder support for the company's strategic direction.

Negatives

• No explicit negatives are stated; however, the completion of the merger remains subject to further conditions.

Risks

• Conditions to the closing of the proposed transaction may not be satisfied, including failure to obtain necessary approvals.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction and the ability of Enzon and Viskase to complete it.
• Viskase's ability to timely deliver financial statements required by the Merger Agreement.
• Anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, financial results, growth, expansion, and tax treatment, may not be realized.
• Potential litigation related to the proposed transaction against Enzon, Viskase, or their officers/directors.
• Possible disruptions from the proposed transaction that could harm Enzon's or Viskase's respective businesses.
• Viskase's ability to retain, attract, and hire key personnel.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties due to the announcement or completion of the transaction.
• Business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect financial performance.
• Certain restrictions during the pendency of the proposed transaction may impact Enzon's or Viskase's ability to pursue certain business opportunities or strategic transactions.
• Uncertainty regarding the exchange ratio and relative ownership levels at the closing of the merger.
• Estimates regarding future revenue, expenses, and capital requirements following the merger closing.
• Legislative, regulatory, and economic developments.
• Unpredictability and severity of catastrophic events, including terrorism, trade wars, or war/hostilities.
• Other risks and uncertainties detailed in the Registration Statement under "Risk Factors" and in periodic public filings.

Future Outlook

The proposed transaction involving Enzon and Viskase is moving forward with stockholder approval for both the reverse stock split and the merger. The closing of the merger remains subject to the satisfaction or waiver of remaining conditions. The combined company aims to quote its common stock on the OTCQB tier of the OTC market.

Industry Context

StockSavvy.ai notes that consolidation through mergers and acquisitions is a common strategy in the pharmaceutical and related industries, often aimed at achieving economies of scale, expanding product portfolios, or streamlining operations. Reverse stock splits are frequently used by companies to increase their share price, meet listing requirements, or improve market perception, particularly ahead of significant corporate actions like mergers. The move to quote on the OTCQB tier suggests a strategic decision regarding market visibility and liquidity for the combined entity.

Comparison to Industry Standards

• StockSavvy.ai observes that reverse stock splits are a common mechanism for companies, particularly those with low share prices, to meet exchange listing requirements or improve stock market perception. For example, companies like Aeterna Zentaris Inc. (AEZS) and Sorrento Therapeutics, Inc. (SRNE) have executed reverse splits to maintain compliance or facilitate strategic transactions.
• Mergers and acquisitions are standard practice in the pharmaceutical sector, with numerous examples such as the Pfizer-Wyeth merger or the AbbVie-Allergan acquisition, demonstrating the industry's trend towards consolidation for market share and pipeline expansion.
• The approval percentages (55.2% and 57.1%) for the proposals are above the simple majority required, indicating sufficient but not overwhelming shareholder consensus, which is typical for significant corporate actions.

Stakeholder Impact

• Shareholders: Will experience a 1-for-100 reverse stock split, potentially increasing share price but reducing the number of shares held. Their ownership will also be impacted by the merger with Viskase.
• Employees: Potential disruptions and changes to business operations from the proposed transaction could affect employees of both Enzon and Viskase. Viskase's ability to retain, attract, and hire key personnel is a specific risk.
• Customers/Suppliers: Potential adverse reactions or changes to relationships with customers and suppliers resulting from the announcement or completion of the proposed transaction.

Next Steps

• Satisfaction or waiver of the remaining conditions to closing set forth in the Merger Agreement.
• Consummation of the proposed transaction between Enzon and Viskase.
• Quoting the common stock of the combined company on the OTCQB tier of the OTC market of the OTC Markets Group, Inc.

Key Dates

Recommendation

The stockholder approvals are a necessary step for the merger, which could be transformative. However, the transaction is not yet closed and is subject to significant risks and uncertainties. Investors should hold pending further clarity on the merger's completion and the combined entity's future performance.

Keywords

Enzon Pharmaceuticals, Viskase Companies, Merger Agreement, Reverse Stock Split, Stockholder Approval, Consent Solicitation, Corporate Action, SEC Filing, Form 8-K, Pharmaceuticals, Acquisition